

(A) Relative expression levels of *yrbE* and *vacJ* were determined by quantitative real time PCR *in vitro* (n = 6) during growth in LB broth (open circles) and *in vivo* (n = 10 for *yrbE* and n = 9 for *vacJ*) during intestinal colonization (22 h post-infection, grey circles).

(B) Plasmid maintenance of the empty pMMB67EH vector (p,  $Ap^R$ ) and the *yrb* operon expression vector (pyrbF-B,  $Ap^R$ ) in *V. cholerae* is indicated as the ratio of CFU ( $Ap^R$ )/ CFU ( $Sm^R$ ) after 22 h growth in LB broth (open circles) and *in vitro* during intestinal colonization (22 h post-infection, grey circles). A ratio of 1 (dashed line) indicates optimal plasmid stability. Horizontal bars indicate the median of each data set (n = 6).




Figure S2. Mass spectrometry analysis of lipid A extracted from the  $\Delta almG$  mutant. Related to Figure 3.

Lipid A extracted after the M9 to  $M9^{ToxR^{Alm^{+}}}$  transition from  $\Delta almG$  after 8 h was analyzed. Comparable to figure 3 the left graph shows the extracted ion chromatogram of m/z 877.7 (U, representing unmodified lipid A) in blue, m/z 906.2 (M1, representing mono-glycinated lipid A) in orange, and m/z 934.7 (M2, representing di-glycinated lipid A) in red. Only the unmodified lipid A species at m/z 877.7 could be detected, the mono- and di-glycinated lipid A species were below limit of detection. In addition, the high-resolution mass spectrum of the unmodified doubly charged lipid A species with its isotope pattern is displayed in the right graph.




Figure S3. Coomassie-stained gels of whole cell lysates, OM preparations and isolated OMVs derived from WT,  $\Delta yrbE$  and  $yrbE^*$ . Related to Figure 4.

Shown are Coomassie-stained gels loaded with cell equivalents of whole cell lysates or protein equivalents (5  $\mu$ g) of OM preparations and OMVs from WT,  $\Delta yrbE$  and  $yrbE^*$ . Samples were taken at time points 0, 1, 2, 4, 6 and 8 h for whole cell lysates and OM as well as 0, 4 and 8 h for OMVs after transition from M9 to M9<sup>ToxR†</sup>. Molecular mass standards are indicated on the left using either Prestained Protein Marker Broad Range (New England Biolab) or PageRuler<sup>TM</sup> Prestained Protein Ladder 10 - 180 kDa (Thermo Fisher).




Figure S4. OMV production and minimal inhibitory concentrations (MIC) of polymyxin B (PMB) determined for  $\triangle almG$  and  $\triangle almG \triangle yrbE$ . Related to Figure 5.

(A) Quantification of OMV biomass (Bradford) prepared from equivalent OD<sub>600</sub> units of  $\Delta a lmG$ and  $\Delta a lmG \Delta yrbE$  after 8 h cultivation in minimal media M9<sup>ToxR†</sup>. Data is presented as the median with interquartile range (n = 6; \**P* < 0.05).

(B) Shown are minimal inhibitory concentrations (MIC) of polymyxin B (PMB) for the  $\Delta almG$ (n = 12) and  $\Delta almG\Delta yrbE$  mutants (n = 15) along a transition from M9 to M9<sup>ToxR^/Alm^</sup> [(di)glycine-modified lipid A activating conditions using sub-MIC PMB concentrations (0.3 µg/ml)]. Bacteria were allowed to adapt for 2 h after transition into the fresh medium before additional PMB was added in diverse concentrations to determine the MIC. Results are presented as mean ± SD (\*P < 0.05).




Figure S5. Hyper- or hypo-vesiculation by deletion of *yrbE* or overexpression of *yrbF-B* does not affect growth in minimal media  $M9^{ToxR\uparrow}$ . Related to Figure 5.

Shown are growth curves (A, C) and the retrieved area under curve (AUC) values (B, D) for the *V. cholerae* WT,  $\Delta yrbE$  and the complementation strain  $yrbE^*$  (A, B) shifted from M9 to M9<sup>ToxR↑</sup> or the arabinose-inducible strain  $yrbF-B^{pARA}$  shifted from M9 to M9<sup>ToxR↑</sup> with (w) or without (w/o) arabinose (Ara) (C, D). Data is presented as mean values ± SD with the following number of biological replicates: n = 4 for WT and  $\Delta yrbE$  as well as n = 8 for  $yrbE^*$ ,  $yrbF-B^{pARA}$ w Ara and  $yrbF-B^{pARA}$  w/o Ara, respectively.




Figure S6. Minimal inhibitory concentrations (MIC) of antimicrobial substances and OMV production for various *V. cholerae* strains used in this study. Related to Figure 5. (A and B) Shown are minimal inhibitory concentrations (MIC) of bile (A) and SDS (B) for WT,  $\Delta vrbE$  and the complementation strain  $vrbE^*$  grown in M9. Data is presented as the median

with interquartile range (\*P < 0.05) with the following number of biological replicates: MIC of bile for WT (n = 22), for  $\Delta yrbE$  (n = 8) and for yrbE\* (n = 18) as well as n = 12 for the MIC of SDS for all strains tested.

(C) Relative expression levels of *yrbE* in the arabinose-inducible *yrbF-B* variant were determined by quantitative real time PCR *in vitro* during growth in M9<sup>ToxR↑</sup> with (w) or without (w/o) arabinose (Ara) (n = 6; \*P < 0.05).

(D) Quantification of OMV biomass (Bradford) prepared from equivalent OD<sub>600</sub> units of the arabinose-inducible *yrbF-B* variant. Values were obtained after 4 and 8 h cultivation in minimal

media M9<sup>ToxR<sup>↑</sup></sup> with (w) or without (w/o) arabinose (Ara). Data is presented as the median with interquartile range (n = 6; \*P < 0.05).

(E) Shown are the minimal inhibitory concentrations (MIC) of the arabinose-inducible strain  $yrbF-B^{pARA}$  against polymyxin B (PMB) along a transition from M9 to M9<sup>ToxR^/Alm^</sup> [(di)glycine-modified lipid A activating conditions using sub-MIC PMB concentrations (3 µg/ml)] with (w) or without (w/o) arabinose (Ara). Bacteria were allowed to adapt for 2 h after transition into the fresh medium before additional PMB was added in diverse concentrations to determine the MIC. Results are presented as mean ± SD (n = 6; \*P < 0.05).

Oligonucleotides	Source
almG XbaI 1	This non or
AATTCTAGAGGCAAACAGTTAGTGAAGGG	This paper
almG_BamHI_2	This paper
TATGGATCCTTTTTTCCGACTTATCGGCTTA	
almG_BamHI_3	This paper
AAAGGATCCAAGCAATTCGGTGTATCTAAGA	F 0F
almG_SacI_4	This paper
AATGAGCTCTCCACAATAAGTTGTGCCAAAG	
lacZ_XbaI_1 TATCTAGAATGTACGCCGTAGAGCAAAG	This paper
lacZ BamHI 2	
TAGGATCCATGGCGAGTCACTTGGCTAA	This paper
lacZ SphI 3	
ATGCATGCGTGTGGGAATGTGACGAT	This paper
lacZ SacI 4	
ATGAGCTCTTATTGTGGGGGATGACCTTTAAAG	This paper
araC BamHI 1	
AAAGGATCCAGACACTTTTGTTACGCGTTTT	This paper
araC_SphI_2	This paper
ATTGCATGCTTATGACAACTTGACGGCTAC	This paper
yrb_SacI_1	This paper
AAAGAGCTCGCGATATTGGCAATGTTTGAAC	
yrb_SphI_2	This paper
AAAGCATGCGATAAGGATAATTAATTGGAATC	The paper
yrb_EcoRI_3	This paper
AAAGAATTCTCAGGATGTCGACCTAACAG	1 1
yrb_XbaI_4 TTTTCTAGAGATTAAGGTTACGGATCAGTTC	This paper
para SphI 1	
AAAGCATGCAAAGCCATGACAAAAACGCG	This paper
para EcoRI 2	
GAATTCGCTAGCCCAAAAAAAC	This paper
almG pGPphoA SacI	
TTGAGCTCGTTAACCTCAGGTTTATTTTATTT	This paper
almG pGPphoA KpnI	This non on
ATTGGTACCTTACTTAAAACGCCGATAAAGC	This paper
yrb_operon_SacI_1	This paper
TTTGAGCTCTTTCAGGATGTCGACCTAA	
yrb_operon_XbaI_2	This paper
AAATCTAGACTATCCACAATTCACCTCTGC	This puper
VC2519_XbaI_up_fw	(Roier et al., 2016)
AAATCTAGACTTAGTCACCATCAAAAATT	(
VC2519_XmaI_down_rv	This paper
AAACCCGGGCTCCGCCACATCTTCACGTT	
	This paper
GTTGCATGTTTAATTCCCAAACATCAATGCGG comp_vrbE* 2	_
COMP_YTDE*_2 TTTGGGAATTAAACATGCAACAAACACGAAAAATTG	This paper

Table S1. List of oligonucleotides used in this study, related to STAR Methods